Syon Capital LLC Has $1.86 Million Holdings in Pfizer Inc. (NYSE:PFE)

Syon Capital LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 111.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,444 shares of the biopharmaceutical company’s stock after purchasing an additional 33,961 shares during the period. Syon Capital LLC’s holdings in Pfizer were worth $1,855,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc bought a new position in Pfizer during the third quarter worth about $30,000. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new position in Pfizer in the third quarter valued at approximately $34,000. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in Pfizer in the fourth quarter valued at approximately $36,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Trading Down 3.8 %

Shares of PFE stock traded down $1.00 on Thursday, hitting $25.27. 47,517,229 shares of the company’s stock traded hands, compared to its average volume of 41,953,172. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37. The company’s fifty day simple moving average is $27.05 and its 200 day simple moving average is $28.50. The stock has a market capitalization of $143.09 billion, a price-to-earnings ratio of 71.14, a P/E/G ratio of 1.19 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.14 EPS. Equities analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.65%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.